Table of Contents
Dr. Adil Ali asks Dr. John Patton (CSO) and Dan Miller (Formulation Development Lead) all about eSpraye's drug pipeline.
eSpraye (Pulmonary fibrosis, Dry Powder) - Onyx Analyst
Related
How India is leading a cancer revolution
The story of how an Indian biotech startup slashed the cost of CAR-T from $475,000 to just $30,000 and started a revolution in global CAR-T therapy access.
Comments